Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The Smokerface poster campaign for adolescent smoking prevention in schools: A cluster-randomized controlled trial.

European journal of cancer (Oxford, England : 1990)·2026

Same author

Integration and validation of complementary ex vivo assays for functional precision oncology.

NPJ precision oncology·2026

Same author

A pooled analysis of phase 2 clinical trials in advanced chordoma.

European journal of cancer (Oxford, England : 1990)·2026

Same author

Mutant IDH1 blocks neutropoiesis by repressing myeloid progenitor programs.

Blood·2026

Same author

Glucocorticoids induce a phagocytic C1Q+ macrophage phenotype primed for IFNγ-dependent CXCL9 secretion.

Scientific reports·2026

Same author

Clinically actionable genomic and transcriptomic landscape of advanced neuroendocrine neoplasms.

Med (New York, N.Y.)·2026

Same journal

Psychological stress drives aging-like hematopoietic stem cell dysfunction through a brain-gut-bone marrow axis.

Cell stem cell·2026

Same journal

Human stem cell-based embryo model governance: Insights from Japan.

Cell stem cell·2026

Same journal

From reconstruction to intervention: Engineered organoids as living therapeutic depots.

Cell stem cell·2026

Same journal

Long-term lessons from MATCH01 macrophage therapy in cirrhosis.

Cell stem cell·2026

Same journal

Beyond apoptosis: LSC state dictates metabolic and anti-apoptotic vulnerabilities.

Cell stem cell·2026

Same journal

Outside the niche: Gut microbiota relay psychological stress to hematopoietic stem cell dysfunction.

Cell stem cell·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 11, 2025

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens

Published on: August 25, 2023

Let's get functional: Drug sensitivity profiling to enable precision sarcoma medicine.

Claudia R Ball¹, Stefan Fröhling²

¹Department of Translational Medical Oncology, National Center for Tumor Diseases (NCT), NCT/University Cancer Center Dresden, a partnership between German Cancer Research Center (DKFZ), Faculty of Medicine and University Hospital Carl Gustav Carus, Dresden University of Technology (TUD), and Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany; Translational Medical Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Dresden University of Technology (TUD), Dresden, Germany; Faculty of Biology, Dresden University of Technology (TUD), Dresden, Germany; German Cancer Consortium (DKTK), Partner Site Dresden, Dresden, Germany.

|October 4, 2024

Summary

This summary is machine-generated.

Short-term cultures from patient tumors can screen multiple drugs for bone and soft tissue sarcomas. This advance offers personalized treatment options for high-risk cancer patients.

More Related Videos

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Related Experiment Videos

Last Updated: Jun 11, 2025

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens

Published on: August 25, 2023

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Area of Science:

Oncology
Translational Medicine
Cancer Therapeutics

Background:

Drug sensitivity profiling in patient-derived tumor models is crucial for cancers with limited treatment options.
Bone and soft tissue sarcomas represent high-risk malignancies often lacking effective therapeutic strategies.

Purpose of the Study:

To evaluate the utility of short-term cultures from bone and soft tissue sarcomas for drug sensitivity profiling.
To determine if this approach enables clinically meaningful screening of drugs and drug combinations.

Main Methods:

Establishment of short-term cultures from patient-derived bone and soft tissue sarcoma samples.
Screening of multiple single-agent drugs and drug combinations for anti-cancer activity in these cultures.

Main Results:

Short-term cultures successfully facilitated drug sensitivity profiling.
The methodology allowed for clinically relevant screening of various therapeutic agents and combinations.

Conclusions:

Short-term tumor cultures are a viable and effective tool for drug sensitivity screening in bone and soft tissue sarcomas.
This approach represents a significant advancement in personalized cancer care for these challenging diseases.